Menin Inhibitor Enters Diabetes: Novel Mechanism, No Human Data, High Evidentiary Bar Ahead

Kura Oncology Launches Caspian Therapeutics with $50M Financing

Kura Oncology, a biopharmaceutical company, has launched Caspian Therapeutics, a new subsidiary focused on developing small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian secured $50 million in financing, led by BVF Partners, with participation from T1D Fund, Invus, Montanova, Eli Lilly and Company, and Kura Oncology. The new company will advance KO-7246, a next-generation menin inhibitor, through IND-enabling development and initial clinical proof-of-concept in diabetes. Preclinical studies with KO-7246 demonstrated selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes. Kura Oncology retains approximately half ownership of Caspian and board representation, while maintaining its focus on oncology.

• Kura Oncology has strategically spun off its diabetes and cardiometabolic assets into a new, separately financed entity, Caspian Therapeutics. This move allows Kura to maintain its focus on oncology while retaining significant ownership (approximately half) in Caspian. The $50 million financing, led by BVF Partners and including major investors like Eli Lilly and Company and T1D Fund, provides dedicated capital for Caspian to advance its pipeline.
• Caspian's lead candidate, KO-7246, a next-generation menin inhibitor, has shown promising preclinical results. Studies demonstrated its ability to selectively stimulate pancreatic β-cell proliferation, expand functional β-cell mass, and increase endogenous insulin production. These effects led to progressive improvements in insulin production and glycemic control across both Type 1 and Type 2 diabetes animal models, with improvements persisting after treatment cessation.
• Caspian Therapeutics is pursuing a fundamentally different approach to diabetes treatment by targeting the underlying loss of β-cell function. Unlike most current therapies that manage blood glucose or supplement insulin, menin inhibition aims to restore the body’s endogenous insulin-producing capacity by increasing the number and function of pancreatic β cells. This disease-modifying strategy could offer a durable solution for patients.

KO-7246: Targeting Menin to Restore Endogenous Insulin Production

Recent research has identified several novel therapeutic targets spanning metabolic regulation, immune modulation, and receptor-based signaling pathways. SIRT1, a NAD+-dependent histone deacetylase, has emerged as a prominent target in type 2 diabetes (T2DM), with growing evidence indicating that it regulates glucose-lipid metabolism through deacetylase activity across multiple substrates and is directly or indirectly involved in insulin signaling in adipose tissue, liver, and skeletal muscle. Overexpression of SIRT1 and several SIRT1 activators have been shown to have beneficial effects on glucose homeostasis and insulin sensitivity in diabetic animal models and humans. SIRT3 and SIRT6 have also been identified as playing crucial roles in glucose and lipid metabolism, broadening the sirtuin family as a class of potential therapeutic targets. Separately, free fatty acid receptors (FFARs) — including FFA1/GPR40, FFA4/GPR120, FFA2/GPR43, FFA3/GPR41, and GPR84 — have been recognized as key therapeutic targets given their roles in energy homeostasis, with impairment of these processes forming part of the pathology of obesity and T2DM.

In the domain of incretin-based and GPCR-targeted therapies, GLP-1 receptor agonists are currently used in the treatment of T2DM, and research has expanded to explore dual and triple agonist peptides that activate two or more GPCRs simultaneously. Studies in Gcgr-/-Glp1r-/- mice revealed extensive functional plasticity in the enteroinsular axis, with compensatory mechanisms involving glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin A receptor (Cckar), and G protein-coupled receptor 119 (Gpr119) sustaining nutrient-dependent regulation of insulin secretion. Combination strategies have also been investigated, with twelve weeks of combined glucokinase activator (Piragliatin) and GLP-1 receptor agonist exendin-4 treatment in db/db mice resulting in significant decreases in body weight gain, food consumption, random glucose, and %HbA1c, while attenuating the hepatic steatosis associated with glucokinase activator monotherapy. Additionally, leucine combined with phosphodiesterase 5 inhibition demonstrated synergy through SIRT1/AMPK signaling, reducing fasting glucose by 38% (P<0.002) and insulin by 37% (P<0.05) in diet-induced obese mice.

Islet-protective and immune-modulatory approaches represent a further frontier. The novel labdane diterpenoid scoparicol E, isolated from Scoparia dulcis, demonstrated antiapoptotic activity in islet cells by suppressing the Bax/Bcl-2/Caspase-3 pathway, preventing cytochrome c release, and restoring mitochondrial membrane potential in MIN6 cells. In autoimmune diabetes, Robo4 — expressed on endothelial cells — has been identified as a regulator of pancreatic vascular endothelial permeability, with Robo4-deficiency resulting in increased leukocyte infiltration and faster diabetes development, while in vivo administration of Slit2 modestly delayed hyperglycaemia and ameliorated islet inflammation. In type 1 diabetes, the immunogenic peptide DiaPep277, derived from the 60-kDa heat shock protein (hsp60), demonstrated 100% immunization efficacy in a randomized, double-blind, phase Ib/II clinical trial, with cytokine production dominated by interleukin-10 and declining proliferative responses to the peptide proposed as an immunological biomarker for clinical efficacy.

Addressing Diabetes' Unmet Need: Beyond Glucose Management

Despite significant advances in pharmacotherapy, a substantial proportion of patients with type 2 diabetes mellitus (T2DM) fail to achieve adequate glycemic control — a gap driven by a complex interplay of biological, behavioral, and systemic factors. Addressing these challenges requires an understanding of both the disease's progressive pathophysiology and the real-world limitations of current treatment paradigms.

• Inadequate glycemic control remains widespread. Only 36% of patients with type 2 diabetes achieve glycemic control with currently available therapies. As of 2011, an estimated 3.1 million (14.9%) patients with type 2 diabetes still reported not taking any medications to treat their condition, underscoring the scale of the treatment gap.

• Progressive beta-cell failure limits long-term treatment efficacy. A significant proportion of beta-cell secretory capacity is thought to be lost well before the diagnosis of T2DM is made. Long disease duration, HbA1c of 9% or higher, and long-term use of therapies that continuously stimulate the beta cell are associated with significant beta-cell dysfunction, ultimately contributing to treatment failure and disease progression.

• Antipsychotic-induced metabolic disturbances compound glycemic risk. Second-generation antipsychotics (SGAs) act directly to impair glycemic control, causing insulin resistance, impaired glucose tolerance, type 2 diabetes, and rarely diabetic ketoacidosis (DKA). Schizophrenia itself is almost certainly causal in many endocrine and metabolic disturbances, making this population especially vulnerable to the adverse metabolic consequences of SGA treatment.

• Patient adherence to combination therapy is inconsistently achieved. Adherence rates for dual therapy regimens ranged from 49% to 80.8%, while fixed-dose combination therapies showed adherence rates ranging from 60.3% to 98.9%. Factors influencing adherence included glycemic control, weight management, economic considerations, complexity of regimens, and demographic factors.

• Patient knowledge gaps around drug side effects undermine informed adherence. A considerable proportion of patients with T2DM treated with sulphonylurea (SU) are not aware of the risks of hypoglycaemia and weight gain associated with their treatment. This information gap exists despite the fact that to most patients treated with SU, it is important that their antidiabetic treatment does not cause hypoglycaemia and/or weight gain.

• Complications substantially escalate disease burden and costs. 72% of patients in the CODE-2 study had at least one complication. In patients with both microvascular and macrovascular complications, the total cost of management was increased by up to 250% compared to those without complications, reinforcing that failure to achieve glycemic control carries significant downstream clinical and economic consequences.

• Intensive glycemic control does not uniformly translate to macrovascular benefit. A metaanalysis of five large randomized trials (UKPDS, PROactive, ACCORD, ADVANCE, and VADT) showed a highly significant reduction in non-fatal myocardial infarction with intensive glycemic control, but no significant differences were observed for non-fatal stroke, cardiovascular mortality, or all-cause mortality. The possible explanations include short trial duration and attenuation of benefit by increased hypoglycaemia-related mortality in patients with pre-existing cardiovascular disease.

Menin Inhibition: A Novel Pathway for Diabetes Regeneration

The launch of Caspian Therapeutics by Kura Oncology marks a pivotal moment, signaling a bold expansion of menin inhibition beyond its established oncology focus into the vast landscape of diabetes and cardiometabolic diseases. With KO-7246, a next-generation menin inhibitor, Caspian aims to tackle the root causes of metabolic dysfunction, particularly the loss and dysfunction of pancreatic β-cells.

Research has illuminated menin's complex role, not only as a tumor suppressor encoded by the MEN1 gene but also as a crucial regulator of β-cell proliferation and GLP-1 signaling. Studies indicate that menin suppresses β-cell proliferation and can inhibit GLP-1 receptor transcript levels and downstream phosphorylation pathways. By inhibiting menin, KO-7246 has demonstrated in preclinical models the ability to selectively expand β-cells, boost endogenous insulin production, and improve glycemic control in both Type 1 and Type 2 diabetes. Furthermore, menin inhibition has been shown to increase GLP-1 expression in enteroendocrine cells, enhancing a key hormone for blood glucose regulation.

This novel approach offers the potential for a truly disease-modifying therapy, moving beyond symptomatic management to address the underlying cellular deficits in diabetes. Kura's strategic decision to spin off Caspian allows it to maintain focus on its oncology pipeline while retaining significant upside in this new venture, backed by a substantial $50 million financing round. This dedicated funding will be critical for advancing KO-7246 through early clinical development and establishing proof-of-concept.

However, the path forward is not without its considerations. Given menin's role as a tumor suppressor and its involvement in cell division and genome stability, the long-term safety profile of menin inhibition, particularly regarding potential oncogenic risks, will require rigorous evaluation. Moreover, translating promising preclinical results into consistent and durable clinical benefits in human diabetes patients, a condition characterized by complex inter-organ cross-talk and diverse etiologies, remains a significant hurdle. Finally, entering the highly competitive diabetes market demands a clear demonstration of superior efficacy or a unique patient benefit to differentiate from existing and emerging therapies. Despite these challenges, the potential for menin inhibitors to regenerate β-cells and enhance GLP-1 signaling represents an exciting new frontier in the quest for more effective diabetes treatments.